You are here


New share capital registered

30 July 2008: Reference is made to resolution by the general meeting 18 June 2008, as well as prospectus dated 26 June 2008 and press release 10 July 2008 regarding the rights offering in NorDiag ASA.

The new share capital in NorDiag ASA of NOK 5,343,755.90 is now registered in the Norwegian Registry of Business Enterprises.

CEO Mårten Wigstøl
Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections.

The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information, please see

Read the Notice in Norwegian here